Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Registry screening aims to close gaps in heart failure care

NCT ID NCT07154758

Disease control Sponsor: Region Stockholm Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study uses the Swedish Heart Failure Registry to identify people with heart failure and reduced ejection fraction who may need medication adjustments, iron deficiency screening, device therapy, or physiotherapy. Researchers will compare outcomes for 500 patients who receive this registry-based screening and referral to 500 patients receiving usual care. The goal is to see if this approach helps more patients get the treatments they need.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
registry-based screening and referral for guideline-directed medical therapy optimization
What this could lead to
If successful, this approach could help more heart failure patients receive optimal medications and treatments, potentially improving survival and quality of life.
What could go wrong
This is an early-stage implementation study, not testing a new drug. Success depends on whether screening and referral actually change outcomes in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Registration in SwedeHF with an index date after January 1st 2023 for the screening arm. For controls, hospital access after January 1st 2023. * HF duration \>6 months to ensure that patients had time to go through the treatment optimization process as recommended by the guidelines. * HF with reduced EF (HFrEF) defined as categorical or continuous EF ≤40% * Capable of giving signed informed consent (for the screening arm) Exclusion Criteria: * Under optimization of HF therapy * In judgment of the investigator unlikely to understand or comply with study procedures Control population is sex and age matched with the SwedeHF screening arm (1:1)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hemse vårdcentral

    RECRUITING

    Hemse, Sweden

  • Karolinska University Hospital

    RECRUITING

    Stockholm, Sweden

  • Länssjukhuset Ryhov

    RECRUITING

    Jönköping, Sweden

  • Sahlgrenska Universitetssjukhuset

    RECRUITING

    Gothenburg, Sweden

  • St Görans hospital

    RECRUITING

    Stockholm, Sweden

  • Södersjukhuset

    RECRUITING

    Stockholm, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.